Takaaki Tokito

9.1k total citations
92 papers, 1.3k citations indexed

About

Takaaki Tokito is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Takaaki Tokito has authored 92 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 67 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Takaaki Tokito's work include Lung Cancer Treatments and Mutations (52 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Lung Cancer Diagnosis and Treatment (24 papers). Takaaki Tokito is often cited by papers focused on Lung Cancer Treatments and Mutations (52 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Lung Cancer Diagnosis and Treatment (24 papers). Takaaki Tokito collaborates with scholars based in Japan, United States and Germany. Takaaki Tokito's co-authors include Koichi Azuma, Tomoaki Hoshino, Hidenobu Ishii, Kazuhiko Yamada, Akihiko Kawahara, Takashi Kinoshita, Norikazu Matsuo, Masayoshi Kage, Toshiaki Takahashi and Hirotsugu Kenmotsu and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Takaaki Tokito

82 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takaaki Tokito Japan 18 943 726 198 188 171 92 1.3k
Kazushige Wakuda Japan 24 1.1k 1.1× 1.0k 1.4× 207 1.0× 224 1.2× 182 1.1× 117 1.6k
Yusuke Chihara Japan 13 641 0.7× 435 0.6× 154 0.8× 77 0.4× 86 0.5× 60 898
Shingo Takanashi Japan 15 503 0.5× 418 0.6× 347 1.8× 221 1.2× 84 0.5× 48 1.0k
Ou Yamaguchi Japan 19 910 1.0× 677 0.9× 132 0.7× 87 0.5× 86 0.5× 88 1.1k
Ryoji Kato Japan 13 1.2k 1.2× 711 1.0× 206 1.0× 82 0.4× 98 0.6× 24 1.4k
Filippos Koinis Greece 17 684 0.7× 252 0.3× 257 1.3× 125 0.7× 235 1.4× 43 997
Masahiro Morise Japan 17 707 0.7× 752 1.0× 206 1.0× 59 0.3× 141 0.8× 112 1.1k
Fumiyoshi Ohyanagi Japan 20 561 0.6× 673 0.9× 263 1.3× 87 0.5× 199 1.2× 68 1.1k
Hiroki Ueda Japan 16 653 0.7× 307 0.4× 116 0.6× 125 0.7× 112 0.7× 58 916
Keita Kudo Japan 13 1.0k 1.1× 611 0.8× 173 0.9× 100 0.5× 107 0.6× 35 1.3k

Countries citing papers authored by Takaaki Tokito

Since Specialization
Citations

This map shows the geographic impact of Takaaki Tokito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takaaki Tokito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takaaki Tokito more than expected).

Fields of papers citing papers by Takaaki Tokito

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takaaki Tokito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takaaki Tokito. The network helps show where Takaaki Tokito may publish in the future.

Co-authorship network of co-authors of Takaaki Tokito

This figure shows the co-authorship network connecting the top 25 collaborators of Takaaki Tokito. A scholar is included among the top collaborators of Takaaki Tokito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takaaki Tokito. Takaaki Tokito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ishii, Hidenobu, et al.. (2024). Thoracic Angiosarcoma Arising from Chronic Tuberculous Pyothorax. Internal Medicine. 64(7). 1085–1088. 1 indexed citations
3.
Azuma, Koichi, Kenta Murotani, Akihiko Kawahara, et al.. (2024). Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy. Cancer Immunology Immunotherapy. 73(11). 214–214. 1 indexed citations
4.
Katoh, Hiroshi, et al.. (2024). CD163+ Tumor-Associated Macrophage Recruitment Predicts Papillary Thyroid Cancer Recurrence. Journal of Surgical Research. 303. 532–544. 2 indexed citations
5.
Tsuboi, Masahiro, Haruyasu Murakami, Hideyuki Harada, et al.. (2024). Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study. Thoracic Cancer. 15(20). 1541–1552. 1 indexed citations
6.
7.
Ikeda, Satoshi, Takashi Ogura, Takaaki Tokito, et al.. (2023). MA18.08 A Phase 2 Study of Carboplatin, Etoposide and Nintedanib for Unresectable Small-Cell Lung Cancer with Idiopathic Pulmonary Fibrosis. Journal of Thoracic Oncology. 18(11). S168–S168. 1 indexed citations
8.
9.
Matsuo, Norikazu, Koichi Azuma, Kenta Murotani, et al.. (2023). Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors. Thoracic Cancer. 14(15). 1362–1367. 15 indexed citations
10.
Azuma, Koichi, Norikazu Matsuo, Kenta Murotani, et al.. (2023). Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors. Cancer Medicine. 12(19). 19471–19479. 7 indexed citations
11.
Miura, Satoru, Yasuhiro Koh, Koichi Azuma, et al.. (2023). Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC Cancer. 23(1). 6–6. 5 indexed citations
12.
Shimokawa, Tsuneo, Yuichi Takiguchi, Toshihiro Misumi, et al.. (2022). A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630. Clinical Cancer Research. 28(20). 4402–4409. 19 indexed citations
13.
Morise, Masahiro, Hiroshi Sakai, Terufumi Kato, et al.. (2021). MO19-2 INSIGHT2: Tepotinib + osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp. Annals of Oncology. 32. S309–S309.
14.
Toyozawa, Ryo, Kota Itahashi, Yutaka Fujiwara, et al.. (2021). 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703). Annals of Oncology. 32. S1002–S1003. 4 indexed citations
15.
Horinouchi, Hidehito, Naoyuki Nogami, Hideo Saka, et al.. (2021). Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study. Cancer Science. 112(8). 3255–3265. 40 indexed citations
16.
Horinouchi, Hidehito, Shinji Atagi, Satoshi Oizumi, et al.. (2020). Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study. Cancer Medicine. 9(18). 6597–6608. 31 indexed citations
17.
Ishii, Hidenobu, Koichi Azuma, Kazuko Sakai, et al.. (2020). Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib. Scientific Reports. 10(1). 691–691. 10 indexed citations
18.
Horinouchi, Hidehito, Naoyuki Nogami, Hideo Saka, et al.. (2019). Safety/Tolerability of 1L Pembrolizumab+Chemotherapy in Japanese Patients with Metastatic Nonsquamous NSCLC: KEYNOTE-189. 3–9.
19.
Ishii, Hidenobu, Koichi Azuma, Kazuko Sakai, et al.. (2015). Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget. 6(31). 30850–30858. 65 indexed citations
20.
Ishii, Hidenobu, Koichi Azuma, Kazuko Sakai, et al.. (2015). Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma. Annals of Oncology. 26. vii138–vii138.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazushige Wakuda Breakdown of academic impact, for papers by Yusuke Chihara Breakdown of academic impact, for papers by Shingo Takanashi Breakdown of academic impact, for papers by Ou Yamaguchi Breakdown of academic impact, for papers by Ryoji Kato Breakdown of academic impact, for papers by Filippos Koinis Breakdown of academic impact, for papers by Masahiro Morise Breakdown of academic impact, for papers by Fumiyoshi Ohyanagi Breakdown of academic impact, for papers by Hiroki Ueda Breakdown of academic impact, for papers by Keita Kudo
Rankless by CCL
2026